Biotechnology - Xtandi

Filter

Current filters:

Xtandi

Popular Filters

Promising emerging agents for triple negative breast cancer

08-04-2014

Due to the heterogeneity of triple negative breast cancer, the most promising emerging agents in development…

Astellas PharmaBiotechnologyMarkets & MarketingMedivationniraparibOncologyTesaroXtandi

FDA backs Medivation and Astellas' prostate cancer drug Xtandi

03-09-2012

USA-based Medivation (Nasdaq: MDVN and Japanese drug major Astellas Pharma (TYO: 4503) say that the US…

Astellas PharmaBiotechnologyenzalutamideMedivationNorth AmericaOncologyPharmaceuticalRegulationXtandi

Company Spotlight

ImmunoGen

ImmunoGen

Back to top